Article

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

2019-04-12

Abstract excerpt

Beyond acquired mutations in the estrogen receptor (ER), mechanisms of resistance to ER-directed therapies in ER+ breast cancer have not been clearly defined. We conducted a genome-scale functional screen spanning 10,135 genes to investigate genes whose overexpression confer resistance to selective estrogen receptor degraders. Pathway analysis of candidate resistance genes demonstrated that the FGFR, ERBB, insulin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 856ba3cf-a901-571e-8ee2-66ce65053ae3
DOI: 10.1101/605436

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerDOI 10.1101/605436Read

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.Semantic proximity Read

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerSemantic proximity Read

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read

Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancerSemantic proximity Read

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity Read

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.Semantic proximity Read

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read